Alpha 2.0
Login Register
» Authors » Kelli R Franzenburg

Kelli R Franzenburg

Explore the profile of Kelli R Franzenburg including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 8
Followers 0
Related Specialties
Psychiatry
Neurology
Pharmacology
Top 10 Co-Authors
Mark Suett
John M Kane
Roy Eshet
Christoph U Correll
Eran Harary
Orna Tohami
Stephen Thompson
Anna Elgart
Nir Sharon
Marko A Mychaskiw
Published In
Neuropsychiatr Dis Treat
Adv Ther
Lancet Psychiatry
BMC Psychiatry
CNS Drugs
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey
Velligan D, Salinas G, Belcher E, Franzenburg K, Suett M, Thompson S, et al.
BMC Psychiatry . 2025 Mar; 25(1):232. PMID: 40069675
Background: Long-acting injectable antipsychotics (LAIs) reduce relapses in schizophrenia; however, most clinicians reserve LAIs for nonadherence with oral antipsychotics (OAs) or severe disease. Methods: US psychiatric clinicians were surveyed regarding...
2.
Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care
Correll C, Rubio J, Citrome L, Mychaskiw M, Thompson S, Franzenburg K, et al.
Neuropsychiatr Dis Treat . 2024 Oct; 20:1995-2010. PMID: 39444923
Despite evidence of benefits beyond those of oral antipsychotics, long-acting injectable antipsychotics (LAIs) are underused in schizophrenia treatment. Underuse may be partially a result of misconceptions held by some healthcare...
3.
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia
Citrome L, Suett M, Franzenburg K, Eshet R, Elgart A, Davis Rd G, et al.
Neuropsychiatr Dis Treat . 2024 Oct; 20:1901-1917. PMID: 39399879
Background: TV46000 is a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone approved for the treatment of schizophrenia in adults. Methods: The RISE study (NCT03503318) compared TV-46000 once monthly (q1m) and...
4.
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial
Kane J, Eshet R, Harary E, Tohami O, Elgart A, Knebel H, et al.
CNS Drugs . 2024 Jul; 38(8):625-636. PMID: 38954317
Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that is approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. In...
5.
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria
Kane J, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, et al.
Lancet Psychiatry . 2023 Nov; 10(12):934-943. PMID: 37924833
Background: TV-46000 is a long-acting, subcutaneous, antipsychotic agent that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension that was approved in April, 2023 for subcutaneous use....
6.
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Robinson D, Suett M, Wilhelm A, Chaijale N, Franzenburg K, Gandhi S, et al.
Adv Ther . 2023 Mar; 40(5):2249-2264. PMID: 36905498
Introduction: Studies evaluating patient and healthcare professional (HCP) preferences regarding long-acting injectable (LAI) antipsychotic agent attributes are lacking. Methods: Surveys were administered to physicians, nurses, and patients who had at...